Biogen Licenses Sage’s GABAA Modulators to Bolster CNS Pipeline
By Pratika Pahwa & Michelle Liu
Pharma Deals Review: Vol 2020 Issue 12 (Table of Contents)
Published: 9 Dec-2020
DOI: 10.3833/pdr.v2020.i12.2576 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a move to strengthen its pipeline, Biogen has agreed to partner with Sage Therapeutics to develop and commercialise zuranolone for major depressive disorder, postpartum depression and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS